Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, the ERASur Study

Launched by ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY · Dec 21, 2022

Keywords

ClinConnect Summary

The ERASur Study is a clinical trial designed to find out if adding a specific type of treatment called total ablative therapy can improve outcomes for patients with a type of colorectal cancer that has spread to a few locations in the body. In this study, researchers will compare the usual treatment, which includes medications given through an IV or taken by mouth (known as systemic therapy), to a combination of systemic therapy and ablative therapy. Ablative therapy aims to destroy cancer cells at specific sites using focused radiation or heat. This trial is important because while the usual treatments help control cancer, it's still unclear if these additional treatments can provide extra benefits for patients at this stage of the disease.

To participate in the trial, patients need to have a confirmed diagnosis of metastatic colorectal cancer that has spread to four or fewer areas, with at least one site being suitable for ablative treatment. Eligible patients must also have completed certain previous treatments and be in good overall health. During the trial, participants can expect to receive either the usual treatment or the combination of treatments, and their progress will be monitored closely. This study is currently looking for participants, and it represents a valuable opportunity to explore potentially more effective treatment options for advanced colorectal cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • PRE-REGISTRATION (STEP 0): Histologically-confirmed metastatic colorectal adenocarcinoma
• • PRE-REGISTRATION (STEP 0): No known microsatellite instable (MSI) tumor
• • PRE-REGISTRATION (STEP 0): No known BRAF V600E mutation
• • PRE-REGISTRATION (STEP 0): Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. No known peritoneal and/or omental metastases. If radiologic studies suggest the presence of peritoneal disease, a diagnostic laparoscopy is recommended to verify the absence of peritoneal implants
• • PRE-REGISTRATION (STEP 0): Primary tumor is already resected OR primary tumor is surgically amenable to resection, as determined by consultation and documentation with surgeon or documentation of discussion in the institutional multi-disciplinary tumor board where a surgeon confirms resectability. Patients with unresectable primary tumors are not eligible
• • PRE-REGISTRATION (STEP 0): Four (4) or fewer apparent sites of metastatic disease based on review by local medical team of baseline radiographic imaging obtained prior to initiation of systemic therapy.
• • Sites of metastatic disease must be radiographically evident, but pathologic confirmation is not required.
• • Liver-only metastatic disease is NOT permitted. For patients with liver metastases, there must be at least one other site of metastasis in addition to the liver to be eligible for this study.
• • Metastatic lesions must be amenable to any combination of surgical resection, microwave ablation, and/or stereotactic ablative body radiation therapy (SABR). SABR is required for at least one lesion. Therefore, the patient must be seen by a radiation oncologist in consultation to verify eligibility.
• * Single sites include:
• • Each hemiliver (right and left), each lobe of the lungs, each adrenal gland, lymph nodes amenable to a single resection or treatment in a single SABR field, bone metastases amenable to treatment in a single SABR field
• • PRE-REGISTRATION (STEP 0): Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
• • PRE-REGISTRATION (STEP 0): A maximum of 16 weeks (4 months) of systemic therapy may be administered prior to pre-registration
• • REGISTRATION (STEP 1): Patients must have no overt evidence of disease progression during systemic therapy prior to registration
• • REGISTRATION (STEP 1): Not eligible for hepatic artery infusion pump (HAIP) therapy or benefit of HAIP therapy is undefined
• • REGISTRATION (STEP 1): Patients must have measurable disease per RECIST v1.1
• • REGISTRATION (STEP 1): Patients must be receiving (or have received) first-line systemic therapy for metastatic disease for a minimum of 16 weeks (4 months) and a maximum of 24 weeks (6 months)
• • REGISTRATION (STEP 1): Prior definitive therapy, including adjuvant chemotherapy, must have been completed at least 12 months prior to diagnosis of metastatic disease
• • REGISTRATION (STEP 1): Not pregnant and not nursing, because this study involves an agent or treatment that has known genotoxic, mutagenic, and teratogenic effects.
• • \* Therefore, for women of childbearing potential only, a negative pregnancy test done =\< 14 days prior to registration is required
• • REGISTRATION (STEP 1): Age \>= 18 years
• • REGISTRATION (STEP 1): Eastern Cooperative Oncology Group (ECOG) performance status: 0-2
• • REGISTRATION (STEP 1): Absolute neutrophil count (ANC) \>= 1,500/mm\^3
• • REGISTRATION (STEP 1): Platelet count \>= 50,000/mm\^3
• • REGISTRATION (STEP 1): Creatinine =\< 1.5 x upper limit of normal (ULN) OR calculated (calc.) creatinine clearance \>= 30 mL/min
• • \* Calculated using the Cockcroft-Gault equation
• • REGISTRATION (STEP 1): Total bilirubin =\< 1.5 x ULN
• • REGISTRATION (STEP 1): Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase \[SGOT\]) / alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase \[SGPT\]) =\< 3.0 x ULN
• • \* In the event of metastatic liver disease, =\< 5 x ULN
• • REGISTRATION (STEP 1): Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Note: HIV testing is not required for eligibility
• • REGISTRATION (STEP 1): No other planned concurrent investigational agents while on study
• Exclusion Criteria:
• • N/A